Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Treasury Shares (2021 - 2025)

Kiniksa Pharmaceuticals International's Treasury Shares history spans 5 years, with the latest figure at $415307.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 81.55% year-over-year to $415307.0; the TTM value through Dec 2025 reached $415307.0, down 81.55%, while the annual FY2025 figure was $415307.0, 81.55% down from the prior year.
  • Treasury Shares reached $415307.0 in Q4 2025 per KNSA's latest filing, down from $418730.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.4 million in Q4 2023 to a low of $415307.0 in Q4 2025.
  • Average Treasury Shares over 5 years is $1.5 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: surged 148.75% in 2023, then plummeted 82.45% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $885021.0 in 2021, then skyrocketed by 96.88% to $1.7 million in 2022, then surged by 37.56% to $2.4 million in 2023, then decreased by 6.1% to $2.3 million in 2024, then crashed by 81.55% to $415307.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Treasury Shares are $415307.0 (Q4 2025), $418730.0 (Q3 2025), and $2.3 million (Q2 2025).